Description

UDILIV 150 MG (1×15)

Indications

UDILIV 150 MG is primarily indicated for the treatment of various liver and biliary disorders. It is commonly prescribed for conditions such as primary biliary cholangitis, intrahepatic cholestasis of pregnancy, and gallstone dissolution. The active ingredient, Ursodeoxycholic acid, helps in improving liver function and promoting bile flow, making it an essential therapeutic option for patients suffering from cholestatic liver diseases.

Mechanism of Action

Ursodeoxycholic acid, the active component of UDILIV, functions by several mechanisms to enhance liver health. It reduces the synthesis of cholesterol in the liver and promotes the solubilization of cholesterol in bile. This action aids in the dissolution of cholesterol gallstones and decreases the risk of cholesterol crystallization. Furthermore, UDILIV enhances the flow of bile, which helps in the elimination of toxic bile acids from the liver, thereby protecting hepatocytes from damage and improving overall liver function.

Pharmacological Properties

UDILIV is characterized by its unique pharmacological properties. Ursodeoxycholic acid is a hydrophilic bile acid that exhibits a low toxicity profile. It is well absorbed in the gastrointestinal tract and undergoes enterohepatic circulation, which prolongs its action. The drug is primarily metabolized in the liver and excreted in the bile. Its pharmacokinetics indicate that peak plasma concentrations are typically reached within 1 to 3 hours post-administration. The half-life of Ursodeoxycholic acid is approximately 3 to 5 hours, allowing for effective management of liver-related conditions with appropriate dosing.

Contraindications

UDILIV 150 MG is contraindicated in patients with known hypersensitivity to Ursodeoxycholic acid or any of its excipients. It should also be avoided in individuals with severe liver impairment, biliary obstruction, or acute inflammation of the gallbladder or bile ducts. Additionally, patients with certain types of gallstones, particularly those that are radiopaque, should not use this medication as it may not be effective in dissolving such stones.

Side Effects

While UDILIV is generally well-tolerated, some patients may experience side effects. Common side effects include gastrointestinal disturbances such as diarrhea, constipation, nausea, and abdominal pain. In rare cases, patients may report allergic reactions, including rash, itching, or swelling. If any severe side effects occur, such as jaundice or significant abdominal discomfort, it is crucial to seek medical attention promptly. Long-term use of UDILIV should be monitored by a healthcare professional to assess liver function and overall health.

Dosage and Administration

The recommended dosage of UDILIV 150 MG varies depending on the specific condition being treated. For adults, the typical starting dose is 150 mg taken orally, usually once daily. In cases of gallstone dissolution, the dosage may be adjusted based on the patient’s response and the size of the gallstones. It is essential to follow the prescribing physician’s instructions regarding dosage and duration of therapy. UDILIV should be taken with food to enhance absorption and minimize gastrointestinal side effects.

Interactions

UDILIV may interact with certain medications, potentially altering their efficacy or increasing the risk of side effects. Notably, it can affect the absorption of fat-soluble vitamins (A, D, E, K) and may interact with medications that are metabolized by the liver. Patients taking anticoagulants, antiepileptics, or certain cholesterol-lowering agents should inform their healthcare provider about all medications they are currently using. It is advisable to conduct regular monitoring when UDILIV is used concurrently with other drugs to ensure safe and effective treatment.

Precautions

Before starting treatment with UDILIV, patients should undergo a thorough medical evaluation to determine the appropriateness of this therapy. Special caution is warranted in patients with liver disease, as the drug’s effects may vary based on individual liver function. Regular monitoring of liver enzymes and overall health is recommended during treatment. Pregnant or breastfeeding women should consult their healthcare provider before using UDILIV, as its safety in these populations has not been fully established. Patients should also be advised to maintain a healthy lifestyle, including a balanced diet and regular exercise, to support liver health.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of UDILIV in managing liver and biliary disorders. Research has shown that Ursodeoxycholic acid can significantly improve liver function tests and reduce symptoms associated with cholestatic liver diseases. In a randomized controlled trial, patients receiving UDILIV exhibited a marked reduction in liver enzyme levels compared to those receiving a placebo. Furthermore, studies have indicated that UDILIV is effective in the dissolution of cholesterol gallstones, with a success rate of approximately 40-50% in appropriately selected patients. These findings underscore the importance of UDILIV as a therapeutic option in the management of liver-related conditions.

Conclusion

UDILIV 150 MG is a valuable medication for the treatment of various liver and biliary disorders. Its active ingredient, Ursodeoxycholic acid, offers multiple benefits, including improved bile flow and liver protection. While generally safe, it is essential for patients to be aware of potential side effects, contraindications, and drug interactions. Regular monitoring and communication with healthcare providers are crucial to ensure the safe and effective use of UDILIV. With appropriate management, patients can experience significant improvements in their liver health and overall well-being.